2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
3. The Critical Path Initiative. Leonard Sacks, Office of Critical Path Programs, FDA 2010;Washington DC: DIA.
5. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-forpurpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-107.
6. Baker M. In biomarkers we trust? Nature Biotechnology 2005;23:297-304.
7. Wong Peggy. Statistical Challenges in Translating Biomarkers into Clinical Utility for Drug Development 2010;46th DIA Annual Meeting. Washington, DC.
8. Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions 2005;03.
11. FDA Guidance for Industry. Adaptive Design Clinical Trials for Drugs and Biologics (draft guidance 2010).
13. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80:203-215.